Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

Technology appraisal guidance
Reference number: TA212
Published: 15 December 2010

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix A decision paper presented to the Institute's Guidance Executive

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix A decision paper presented to the Institute's Guidance Executive

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix A decision paper presented to the Institute's Guidance Executive
15 July 2013
(101.62 Kb 29 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 11 July 2013